Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. - Wikidata - wikimedia - TriplyDB

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

http://www.wikidata.org/entity/Q33938055

about

New treatment options against gram-negative organisms Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.Ceftaroline fosamil: drug profile and clinical data.Effect of ceftaroline on normal human intestinal microflora.Ceftaroline fosamil: a brief clinical review.Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics Ceftaroline: a cephalosporin with expanded Gram-positive activity.Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.In vitro activity of new cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008-2011.In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Current and novel antibiotics against resistant Gram-positive bacteria Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit Ceftaroline in complicated skin and skin-structure infections.Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.Inhibition of Streptococcus pneumoniae penicillin-binding protein 2x and Actinomadura R39 DD-peptidase activities by ceftaroline.Molecular typing, virulence traits and antimicrobial resistance of diabetic foot staphylococci Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.Emerging cephalosporins.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.What is in the pipeline for Gram-negative pathogens?In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study Current challenges in treating MRSA: what are the options?Activity of ceftaroline against Enterococcus faecium PBP5.Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.Newer developments in the treatment of Gram-positive infections.Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.Ceftaroline for complicated skin and skin-structure infections.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.

P2860

Q21194906-0D86FC17-0420-4698-98E3-26E54A2C741F Q24646677-D8DC7DE5-3D71-4411-A602-89D01532879F Q24672937-BD6C932B-81BA-45C9-997A-53B2546B91F5 Q33613654-0AC370DB-0286-48E4-9B90-FC8DD71E5EFC Q33657212-FD8CF08F-2089-40BA-AAB2-70EDA4167D66 Q33772804-7DEAAD0C-2DE5-404D-B1AE-C2BBE2FF04F0 Q33826455-17ACE988-C326-481A-807B-9700670159AE Q33939080-3A065755-F5B5-4857-A3DD-47ED219911AA Q34012457-09972B43-771D-4FDF-883B-269CF1503ED3 Q34016030-6ACCD706-5EBB-4014-99BB-5DD823EB0A75 Q34057475-644CFF4F-163D-4F15-9093-C89251BCF503 Q34363461-A7E999AD-A066-4907-A370-1978D3A3173A Q34483441-E0B72157-AEB7-4875-9E4C-46B9AC96BBF8 Q35004919-1899E04F-A7F1-4179-BBD7-5451916F92E1 Q35026521-97E80601-DCB7-406A-A407-0968049CADE9 Q35065778-F95EA750-3BC9-4F55-B032-8EF435602C57 Q35065798-1A046524-CC32-4CF0-ABD3-183BFA91884B Q35117981-5A21FB93-ECFE-4A5D-A402-1AF89A430C2E Q35191527-510287E3-2D75-4C79-BE0F-50A3A5823D97 Q35427862-1FBAA9DE-6BEB-409E-857B-ADA5D37D8229 Q35715381-2220830E-6321-4127-A40C-25359A375828 Q35752997-5EDFA876-F111-4F5D-95F9-F62E6F1A16DD Q35859931-A601BB0D-BFDC-41EC-A4F9-520B9B86AE35 Q36482771-6D7CE51F-6F46-4AAF-96FC-D815EC9993A0 Q36505456-440A28ED-E4A6-4C9D-B031-F921A747138C Q36662239-F5BB67B0-0D50-4A47-92EC-7AC67A7B4FEE Q36763997-2132E43C-BADA-4D8A-912F-5F68960C9CBF Q36839703-2E6E7831-4F4C-4DAE-82E0-DAF8BA6B1D45 Q36989896-BF4232CF-94BB-40F6-AEC1-60CB4E3E46E8 Q37071199-83C732D6-2614-4653-9FB8-1C93F674EB3F Q37072096-0DBA4C37-A763-4B64-9F68-36679F069A21 Q37077619-53D6B90E-B01F-4497-9EA4-2EF13C3BC419 Q37263425-2B1E5C6D-B522-4B45-82E7-19C01C0681D7 Q37291338-FAFF72DE-1C69-4ED6-BC50-464D7B05B4FF Q37335869-AA14567C-6297-4F1F-A748-3E7531C7968E Q37514259-1B1AE6DF-B9B6-40FF-8A39-AEBD2528FAD7 Q37636151-2E446F45-44F7-4E74-B8E2-60ABF49F5B69 Q37718228-AB0F5F25-75F9-4D1C-8C1C-0B469CE764BB Q37733561-8F5194F9-4136-4823-BBBA-351BCE1E4B45 Q37785546-8D65B6D2-4846-495A-9620-02B331D1115C

P2860

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

http://www.wikidata.org/entity/Q33938055

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Antimicrobial activity and spe ...... ollection of clinical strains.

@ast

Antimicrobial activity and spe ...... ollection of clinical strains.

@en

type

label

Antimicrobial activity and spe ...... ollection of clinical strains.

@ast

Antimicrobial activity and spe ...... ollection of clinical strains.

@en

prefLabel

Antimicrobial activity and spe ...... ollection of clinical strains.

@ast

Antimicrobial activity and spe ...... ollection of clinical strains.

@en

P1433

Q33938055-AB2A451E-E2BC-45B6-931E-AB3CF34DCE7D

P1476

Q33938055-D0A2008C-B128-495A-9A26-37861DA4594A

P2093

Q33938055-14B0BA28-5C32-4A59-93E0-93684563E586

Q33938055-267BE5A5-4136-4E93-B153-35FE18245AD2

Q33938055-43BEE2F3-3958-43BC-8E35-03543A309430

Q33938055-E9C3983F-B36F-4970-917E-71BE852F0104

P2860

Q33938055-04F67415-E468-4C29-B9E5-82B69049C40E

Q33938055-0F421ADB-F569-4226-A6E6-2F2CAACAE147

Q33938055-156CBA86-497A-4BAC-A35B-F7179BEEE0E7

Q33938055-2A609BC0-1448-4921-A93A-AAA7BE74A871

Q33938055-2E912E14-7768-4081-B50A-5BC0E78291E4

Q33938055-49192547-4964-4C36-8DF6-12218D220332

Q33938055-903F9FB8-C367-473C-8317-DEFD8F2E7360

Q33938055-93C45F49-10CB-4453-9833-1B2C3680F3C8

Q33938055-96D3CF27-00AD-4A14-9A46-12247F9AA587

Q33938055-A80917D9-BF80-4B20-9B04-E9CF751D4507

P304

Q33938055-0E9BAAC9-CB6F-4257-9E20-ABDCEE2C5C4D

P31

Q33938055-4933A951-A53A-4206-8519-35052A3B4388

P356

Q33938055-B5188911-36D7-4873-AC06-81523CE9D08D

P407

Q33938055-E934B298-348C-4734-95AC-923791BF63F0

P433

Q33938055-8220E585-C984-4C5D-B90D-3EFA18C8E07E

P478

Q33938055-DEA60C80-EE87-4AD5-9E1F-731C256D2EE0

P50

Q33938055-79AF6D65-E192-429D-BEDB-B7858535A77D

P577

Q33938055-FE4ED7A1-C39F-4BEE-9110-8B580B5163A7

P5875

Q33938055-7D05A667-C76E-4D54-BC9A-9D682C06E2CF

P698

Q33938055-6C5EDF5A-5A1E-4F16-A620-282E5C5DBE75

P921

Q33938055-20B790D4-903D-4656-B135-B5AD670624B8

P932

Q33938055-AC6E2021-7015-4FD4-96BE-3F90F730B2F9

P356

AAC.49.8.3501-3512.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Antimicrobial activity and spe ...... ollection of clinical strains.

@en

P2093

Koné Kaniga

http://www.w3.org/2001/XMLSchema#string

Ronald N Jones

http://www.w3.org/2001/XMLSchema#string

Thomas R Fritsche

http://www.w3.org/2001/XMLSchema#string

Yigong Ge

http://www.w3.org/2001/XMLSchema#string

P2860

Genome and virulence determinants of high virulence community-acquired MRSA

TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.

The impact of penicillin resistance on the outcome of invasive Streptococcus pneumoniae infection in children.

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Streptococcus pneumoniae as an agent of nosocomial infection: treatment in the era of penicillin-resistant strains.

Penicillin-resistant pneumococci-implications for management of community-acquired pneumonia and meningitis.

In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.

In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.

In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci.

A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

P304

3501-3512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.8.3501-3512.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7696675

http://www.w3.org/2001/XMLSchema#string

P698

16048970

http://www.w3.org/2001/XMLSchema#string

P921

P932

1196228

http://www.w3.org/2001/XMLSchema#string